Navigation Links
USC study finds that green tea blocks benefits of cancer drug
Date:2/3/2009

Contrary to popular assumptions about the health benefits of green tea, researchers at the University of Southern California (USC) have found that the widely used supplement renders a cancer drug used to treat multiple myeloma and mantle cell lymphoma completely ineffective in treating cancer.

The study, which found that a component of green tea extract (GTE) called EGCG destroys any anticancer activity of the drug Velcade in tumor-bearing mice, will be published in a future print edition of the journal, Blood. It is now available online at the journal's pre-publication First Edition website.

"Our finding that GTE or EGCG blocked the therapeutic action of Velcade was completely unexpected," says lead author Axel H. Schnthal, PhD, associate professor in the Department of Microbiology and Immunology at the Keck School of Medicine of USC. "Our hypothesis was that GTE or EGCG would enhance the anti-tumor effects of Velcade, and that a combination of GTE with Velcade (or EGCG with Velcade) would turn out to be a superior cancer treatment as compared to treatment with Velcade alone."

Herbal remedies, including green tea, have become a popular remedy for cancer patients dealing with side effects of chemotherapy. However, these supplements are unregulated and, for most, their beneficial and/or detrimental effects have not been qualified through research.

Using preclinical models and tumor-bearing mice, the researchers found that the unusually effective blockage of Velcade's therapeutic activity was based on the chemical interaction between molecules. The EGCG molecule and the Velcade molecule were able to form chemical bonds, meaning that the Velcade molecule could no longer bind to its intended target inside the tumor cells.

Clincal trials to verify these results in humans would be highly unethical to conduct, because of the predictably unfavorable outcome. Nevertheless, the researchers expect the results of the
'/>"/>

Contact: Meghan Lewit
lewit@usc.edu
323-442-3941
University of Southern California
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2
...er company says impact is ,significant and substan...lutant legislation, NEWARK, N.J., July 29 Eric S...th and safety, testified today before,Congress abo...known as CAIR). CAIR would have resulted in dramat...
...ticipants and spectators are reminded to protect t...rays on and off the field, PINELLAS PARK, Fla., J...gerly awaited time to enjoy outdoor sports and act...he summer,-- are conscious of the need to use sunb...
...A, Calif., July 29 On October 30, millions of bre... and loved ones will raise,their glasses in a "Toa... provides an opportunity for anyone,affected by br... cause advocates, thanking supporters, and showing...
...ferers Consider Veins a Cosmetic Issue Despite Exp... Discomfort, CHICAGO, July 29 Varicose veins -...y embarrassed sufferers to cover up, even on,the h...vey, many who suffer from varicose veins aren,t aw...
...Researchers at the University of Minnesota have fo...cognitive impairment in one of four child survivor...of the journal Pediatrics . , Malari...adliest forms of malaria. It only takes one bite f...
... RWSURVEY -- Web-Based Compliance Software Availab...unced the,release of its new web-based compliance ...w.rwsurvey.com ., The web-based software allows u...UA PCI HIPAA Compliance BSA-AML ISO 27001 Cob...
Other Medicine News:Health News:PSEG Supports Quick Congressional Action on Clean Air in Wake of Court's Rescinding of CAIR 2Health News:Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans 2Health News:Video: A 'Toast to the Cure' Set for October 30 Breast Cancer Survivors 'Raise Your Glasses' 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 3Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 4Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:New Web-Based Compliance Program Released by RiskWatch 2
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti
(Date:12/3/2009)DURHAM, N.C., Dec. 3 In response to the increasingly critical role of healthcare information technologies in the evolving healthcare delivery system, Duke Medicine has created the Duke Center for Hea
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3Surgeon Approved Pro Athlete Chiropractor Breaks the 2450 Billion Neck Pain Cycle With Launch of Pillo1 First Eco Luxe Neck Pillow 61153 1Surgeon Approved Pro Athlete Chiropractor Breaks the 2450 Billion Neck Pain Cycle With Launch of Pillo1 First Eco Luxe Neck Pillow 61153 2MinuteClinic Celebrates National Nurse Practitioner Week and Recognizes Role of Practitioners in Helping To Close Primary Care Gap 61151 1MinuteClinic Celebrates National Nurse Practitioner Week and Recognizes Role of Practitioners in Helping To Close Primary Care Gap 61151 2MinuteClinic Celebrates National Nurse Practitioner Week and Recognizes Role of Practitioners in Helping To Close Primary Care Gap 61151 3China Sky One Medical Inc Announces Conference Call to Discuss Third Quarter 2009 Results 14794 1China Sky One Medical Inc Announces Conference Call to Discuss Third Quarter 2009 Results 14794 2China Sky One Medical Inc Announces Conference Call to Discuss Third Quarter 2009 Results 14794 3
...ternational Conference of the American ... Forest Laboratories, Inc. and,Laboratorios Almir...al,trials assessing the efficacy and safety of acl...chronic obstructive pulmonary disease (COPD).,Data...the properties of,aclidinium were also presented a...
...ine and Synta,Pharmaceuticals Corp. (Nasdaq: SNTA... for elesclomol (formerly STA-4783), an investigat...c melanoma. A retrospective analysis,showed that s...elesclomol,and paclitaxel who had not previously r...nt improvement in progression-free survival (PFS),...
Other Medicine Technology:Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 2Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 3Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 4Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 2Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 3Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 4Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 6Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 7
MedLook 3.0
... Manager and Collections Administrator has a maxim...billing models and personalized paper or electroni...ty to facilitate rebilling, ledger notes, follow-u...en Collections Worksheet and efficient collection ...
...ware Associates medical billing and practice manag...ronically, while providing your practice with acco...e interface allows you to see insurance payments, ...ntage of services rendered. You can break these nu...
Infinity Amylase CNPG3 (Liquid)
Medicine Products: